TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04345809

Intervention type: PROCEDURE
Intervention: MESH WHIT OMEGA-3
Description: Mesh placement with Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.

Intervention type: PROCEDURE
Intervention: MESH WITHOUT OMEGA-3
Description: Mesh placement without Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
Study: NCT03128411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: All patients will receive bosutinib at a starting dose of 400 mg QD.
Study: NCT02610725

Intervention type: OTHER
Group type: OTHER
Intervention: Hatha yoga
Description: Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
Study: NCT02030041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D will be given to achieve normal serum levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D will be given to achieve normal serum levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin in a dose of 40 mg will be provided to the study participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin in a dose of 40 mg will be provided to the study participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided to the study participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided to the study participants
Study: NCT00384566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: anit hypertensive medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Anti hypertensive medication
Study: NCT01425996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipotecan® (TLC388)
Description: * Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~* Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~* Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~* Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~* Cohort Ax: TLC388 MTD x 6 dose + 3DCRT
Study: NCT00978198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: oral
Study: NCT02007304

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise training
Description: 12 weeks of lower leg eccentric training
Study: NCT00978198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT01084083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy (IMRT)
Description: Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy (IMRT)
Description: Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV, 90 mg/m\^2 on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV, 90 mg/m\^2 on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV, 75 mg/m\^2 on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV, 75 mg/m\^2 on day 1
Study: NCT02375074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Employment
Description: Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Vocational Rehabilitation
Description: Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
Study: NCT03196830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
Study: NCT02996513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retinol Isotope Dilution (RID)
Description: 13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
Study: NCT03715530

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PAMG-1 immunoassay
Description: The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAMG-1 immunoassay
Description: The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
Study: NCT03347630

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Thoraco-abominal MRI
Study: NCT00529360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
Study: NCT03510273

Intervention type: DEVICE
Group type: OTHER
Intervention: Liger Medical Thermocoagulator
Description: Thermocoagulation treatment by Liger Medical device (US FDA 510K clearance received)
Study: NCT00956293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Mycophenolic Acid (MPA)
Description: A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric Coated Mycophenolic Acid (MPA)
Description: A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A (CsA)
Description: Dosage was based according to blood level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Description: Dosage was based according to blood level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
Study: NCT00327912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Biliopancreatic diversion with Duodenal switch

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux-en-Y Gastric Bypass
Study: NCT03807583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminoven 10%
Description: After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RENORAL
Description: After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care.
Study: NCT02960425

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Delivra TM Livsport preworkout cream
Description: High versus low dose topical creatine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Delivra TM Livsport preworkout cream
Description: High versus low dose topical creatine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Topical placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Topical placebo
Study: NCT04549480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsule
Description: 100 mg dose of bosutinib pediatric capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib tablet
Description: 100 mg dose of bosutinib tablet
Study: NCT01840033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group Piccnut
Description: Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnelled nutritional central catheter
Description: After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
Study: NCT00818493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: IR Capsules, ascending flexible dose, every 4 to 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet (oxycodone and acetaminophen)
Description: One or two 5mg/325 mg tablets every 4 to 6 hours
Study: NCT04402307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chin Tuck Against Resistance
Description: Training in 6 weeks 3 times a day.
Study: NCT02878876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption of milk with sequence A1-A2
Description: Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption of milk with sequence A2-A1
Description: Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
Study: NCT03507127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
Study: NCT03715530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAMG-1 immunoassay
Description: The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
Study: NCT04720469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy
Description: Ablation of untreated thalamus using focused ultrasound to abate tremor.
Study: NCT01082614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigileo
Description: Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV \> 12%.
Study: NCT01750125

Intervention type: DEVICE
Intervention: measure ascending aortic blood flow with pulse wave Doppler
Study: NCT01060787

Intervention type: PROCEDURE
Intervention: Fluocinolone Acetonide 0.59 mg
Description: At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.

Intervention type: PROCEDURE
Intervention: Fluocinolone Acetonide 2.1 mg
Description: At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
Study: NCT03122938

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactoferrin-supplemented formula
Description: Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: formula without lactoferrin supplementation
Description: Subjects consume formula without lactoferrin supplementation (\<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
Study: NCT02761642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Beta
Description: All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
Study: NCT00636181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto AFlex
Description: Positive pressure therapy treatment
Study: NCT04430218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSens
Description: The study involves a surgical implant of cuff electrodes on the nerves in the amputated limb, and muscle recording electrodes the remaining muscles. These will be connected to an implanted stimulator. The stimulator will connect wirelessly to an advanced prosthesis. This may allow a user to move the prosthetic hand intuitively and feel what your prosthesis is touching.
Study: NCT03298815

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Fluid Eye Drops (AFED)
Description: One drop (0.25 mL) in one eye twice daily for up to 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: One drop (0.25 mL) in the other eye twice daily for up to 3 months
Study: NCT02805010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: On Day 1, subjects will receive a single SC dose of abatacept 125mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On Day 1, subjects will receive a single SC dose of placebo
Study: NCT01645345

Intervention type: DEVICE
Group type: OTHER
Intervention: Alma Lasers Accent RF Pixel handpiece
Description: Treatment with fractionated RF Pixel device
Study: NCT00211510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paradigm 722 sensor augmented pump
Description: Subjects use the Paradigm 722 sensor augmented pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paradigm 715 insulin pump
Description: Subjects use the Paradigm 715 insulin pump
Study: NCT03794271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pupilometer guided anesthesia
Description: At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPI guided anesthesia
Description: During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
Study: NCT04753645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handwashing stations at the public places and no soap
Description: BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No activities of the HBCC project and also no soap (Pure Control)
Description: In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soap distributed but no activities of the HBCC project
Description: In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
Study: NCT00636181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP
Description: Positive pressure therapy treatment
Study: NCT04753645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBCC project and Soap
Description: These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
Study: NCT00636181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Positive pressure therapy treatment
Study: NCT03034707

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: biotin
Study: NCT03768427

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EZ 10 mg/Ator 10 mg
Description: FDC of EZ10 mg/Ator 10mg

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EZ 10 mg/Ator 20 mg
Description: FDC of EZ10 mg/Ator 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for FDC EZ/Ator
Description: A single placebo tablet administered orally QD for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for FDC EZ/Ator
Description: A single placebo tablet administered orally QD for 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for atorvastatin
Description: Two placebo tablets matching atorvastatin administered orally QD for 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for atorvastatin
Description: Two placebo tablets matching atorvastatin administered orally QD for 84 days
Study: NCT01440361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
Study: NCT00499668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: 125 mg orally for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron hydrochloride
Description: 24 mg orally for 7 days
Study: NCT00411424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASK8007
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV